Alcoholism and substance abuse have been associated with a polymorphism in a noncoding region of the D 2 receptor gene (the A1 allele of the Taq1 'A' system) in several, [1] [2] [3] [4] [5] [6] [7] [8] [9] but not all 10-13 studies. In addition, the presence of the A1 allele has been associated with lower density of D 2 receptors in the caudate nucleus in one postmortem study.
In 1990, Blum et al 1 reported an association between alcoholism and a polymorphism in a noncoding region of the D 2 receptor gene (the A1 allele of the Taq1 'A' system). This association has been supported in several, [2] [3] [4] [5] but not all subsequent studies. [10] [11] [12] [13] The A1 allele was also found to be associated with prolonged P300 latency, reduced visuospatial preference, and low cerebral glucose utilization, all putative markers of alcoholism and dopamine function deficiency. [15] [16] [17] In addition, the A1 allele has also been associated with substance abuse, [6] [7] [8] [9] which led to its conceptualization as a 'reward gene'. Together, these data suggest that this polymorphism might affect dopamine transmission in a way that predisposes subjects to 'reward seeking' behavior, i.e. behaviors aiming at increasing stimulation of dopamine transmission.
The mechanism underlying the association between the A1 allele and vulnerability to addictive behaviors is unclear, since the Taq1 'A' polymorphism is not located in the coding region of the gene and a direct effect of this polymorphism on the structure of the D 2 receptor gene has been excluded by denaturing gradient gel electrophoresis mutational analysis study. 18 Noble et al 14 described an association between the A1 allele and decreased D 2 receptor density expressed in postmortem striatal samples from alcoholic and nonalcoholic subjects. If replicated, this observation might suggest that this polymorphism is in linkage disequilibrium with an unknown mutation that might affect the expression of the D 2 receptor gene, and that the lower D 2 receptor density associated with the A1 allele might lead to a deficiency in D 2 receptor transmission which, in turn, might trigger behaviors aiming at enhancing dopamine.
The Taq1 'B' system is in strong linkage disequilibrium with the 'A' system. 19 While the 'A' polymorphic site is located 3Ј to the coding sequence of the gene, the 'B' system is within the gene, 5Ј to exon 2. 19 The B1 allele has also been shown to be associated with substance abuse. [6] [7] [8] [9] Because of the importance of this question for the genetics of addiction, we measured both Taq1 'A' and 'B' polymorphism in 70 subjects who underwent in vivo quantitation of D 2 receptor-binding potential with single photon emission computerized tomography (SPECT) and the selective dopamine D 2 receptor radiotracer
The sampled population included 47 healthy controls and 23 subjects with schizophrenia. None of the subjects had a history of alcohol or substance abuse or dependence. Forty-three subjects were A2A2 homozygotes, twenty-three were A1A2 heterozygotes, and four subjects were A1A1 homozygotes. This distribution corresponded to an allele frequency of f(A1) = 0.25. The frequency of A1 carriers was identical in schizophrenics (39%) and controls (38%, Chi-squared P = 0.98). We observed a significant effect of age on [ 123 I]IBZM-binding potential (P Ͻ 0.05), but no effect of clinical status (controls vs schizophrenic subjects) and no effect of the Taq1 'A' allele status. [ , n = 43) ( , n = 34; ns). Fifty-one subjects were B2B2 homozygotes, seventeen were B1B2 heterozygotes, and two subjects were B1B1 homozygotes (f(B1) = 0.16). A1 allele and B1 allele were highly correlated (Chi-square P Ͻ 0.0001). All A2A2 subjects were B2B2 subjects. Among A1 carriers, 70% were B1 carriers and 30% were not B1 carriers. The frequency of A1 carriers was not significantly different in schizophrenics (17%) and controls (31%, Chi-squared, P = 0.19). We observed an effect of age on [ 123 I]IBZM-binding potential (P Ͻ 0.05), no effect of the clinical status and no effect of the Taq1 'B' allele status. ). We observed a diagnosis Ɇ alelle interaction on [ 123 I]IBZM-binding potential (P = 0.021). Schizophrenic subjects with the B1 allele had high [
123 I]IBZM-binding potential values (307 ± 156 ml g −1 , n = 4; age-corrected values: 324 ± 72 ml g −1 ) compared to schizophrenics without the B1 allele (219 ± 67 ml g −1 , n = 19; age-corrected 228 + 72 ml g −1 ), and this was not true in controls (see Table 2 ). However, this finding should be 14 are unclear. A first obvious difference is the methodology -postmortem vs in vivo studies. Postmortem studies are subject to numerous artifacts, associated with agonal states, autolysis time, medications at the time of death, freezing methods and storage time. On the other hand, in vivo measurements are confounded by limited resolution and by the presence of endogenous dopamine. We previously showed that endogenous dopamine occupies in vivo about 20% of D 2 receptors, and that this factor introduces a significant error on the binding measurement. 21 Thus, each approach has its limitations and strengths, but it is unclear how these methodological problems could be related to the discrepancy in the results. A second difference is the clinical composition of the samples (alcoholics and controls vs schizophrenics and controls). However, since no interactions were reported between alcoholism and allele effect of D 2 receptor parameters, this difference cannot explain our failure to replicate the findings.
Another difference between the studies is the D 2 receptor parameter used as outcome measure. While the postmortem study reported K D , B max and binding potential, our study was limited to the binding potential. Because A1 are less frequent than the A2 alleles, A1A1 homozygotes are relatively rare, precluding meaningful statistical treatment of their data. This reason prompted us to pool A1A1 homozygotes with A1A2 heterozygotes in the statistical analysis. However, these subjects carry important information for the hypothesis. If the presence of the A1 allele is associated with a mutation inducing a lower expression of D 2 receptors, the effect should be greater in A1A1 homozygotes than in A1A2 heterozygotes. Accordingly, A1A1 homozygote subjects would be expected to have lower D 2 receptor density than the other two groups (A1A2 and A2A2). This effect was indeed observed in the study of Noble et al. 14 Yet, in our study, the A1A1 homozygotes subjects had [
123 I]IBZM-binding potential in the high range, a finding that is difficult to reconcile with a putative association between this allele and a lower D 2 receptor expression. The same observation was made for the Taq1 'B' system.
In conclusion, Taq1 'A' and 'B' polymorphisms were determined in 70 subjects for which in vivo measurements of striatal D 2 receptor-binding potential were available. In this retrospective study, we failed to replicate the observation that Taq1 polymorphism affects D 2 receptor expression. Additional studies are needed to reconcile the results of this study with previously published reports.
Methods

Subjects
The study was approved by the Yale Institutional Review Board for Human Investigations. Seventy subjects participated in our study. All subjects gave written informed consent. The sampled population included 47 healthy controls and 23 subjects with schizophrenia. None of the subjects had a history of alcohol or substance abuse or dependence. The sample included 60 males and 10 females. Ethnic distribution of the sample was: 50 European Americans (EA), 16 African Americans (AA), three Hispanics and one Asian. Inclusion criteria for healthy controls were: (1) absence of past or present neurological or psychiatric illnesses; (2) no concomitant or past severe medical conditions; (3) no pregnancy. The absence of medical, neurological and psychiatric history (including alcohol and drug abuse) was assessed by history, review of systems, physical examination, routine blood tests, urine toxicology, and EKG. Inclusion criteria for patients with schizophrenia were as follows: (1) diagnosis of schizophrenia according to Diagnostic and Statistical Manual (DSM-IV); (2) no other DSM-IV axis I diagnosis; (3) no history of alcohol or substance abuse or dependence; (4) absence of any psychotropic medication for at least 21 days prior to the study (with the exception of lorazepam, which was allowed at a maximal dose of 3 mg per day up to 24 h prior to the study); (5) no concomitant or past severe medical conditions; (6) no pregnancy; (7) no current suicidal or homicidal ideation; (8) ability to provide informed consent.
SPECT experiments
SPECT experiments were carried out as previously described. 23 [ 123 I]IBZM with specific activity Ͼ 5000 Ci mmol −1 and radiochemical purity Ͼ95% was prepared by direct electrophilic radioiodination of the desiodoprecursor IBZM. A total of [ 123 I]IBZM dose of 9.28 ± 3.12 mCi was given as a bolus followed by a continuous infusion at a constant rate for the duration of the experiment. The ratio of the bolus to hourly infused activity was 3.9. This protocol of administration was previously shown to induce a state of sustained tracer equilibrium in the brain: both the specific and nonspecific activities remained at a constant level from 150 min to the end of the experiment. 23 SPECT data were acquired on two PRISM 3000 (Picker, Cleveland, OH, USA) with high resolution fan beam collimators. Eight consecutive acquisitions of 8 min each were obtained from 180 to 244 min. Plasma metabolite-corrected [
123 I]IBZM steady-state concentration (C SS ) was measured by extraction followed by high pressure liquid chromatography on four venous samples collected at 20-min intervals from 180 to 240 min. SPECT images were reoriented to the cantho-meatal line as visualized by four external fiducial markers glued to the subject's head. The four slices with highest striatal uptake were summed and attenuation corrected assuming uniform attenuation. Standard region of interest profiles (striatum 556 mm 2 , occipital 2204 mm 2 ) were positioned on the summed images. The occipital region was selected as the nonspecific region because: (1) the density of dopamine D 2 receptors is negligible in this region compared to the striatum; 24 (2) this region can be identified with greater reliability than the cerebellum; (3) in humans, [ 123 I]IBZM activity in the occipital region is equal to the nonspecific activity in the striatum. 25 Right and left striatal regions were averaged. Striatal specific binding was calculated as striatal minus occipital activity. The [ 123 I]IBZM-binding potential (ml g −1 ), corresponding to the product of the free receptor density (B max , nM or pmol per g of brain tissue) and affinity (1/K D , nM −1 , or ml of plasma per pmol), was calculated as the ratio of striatal specific binding (Ci per g of brain tissue) to the steady-state free unmetabolized plasma tracer concentration (f 1 C SS , Ci per ml of plasma) measured during scanning session. 23 The Polymorphism determination DNA was extracted from whole blood by standard methods. We used PCR-formatted assays for the Taq1 'A' 27 and 'B' 28 system.
Statistical analysis
Allele frequency is reported as f(A1) = [2(A1A1) + (A1A2)]/2N. Given the small number of A1A1 subjects, we followed the method of Noble et al, 14 and classified subjects into A1 carriers, pooling A1A2 and A1A1 subjects, and A1 noncarriers (ie A2A2 subjects). We followed the same method for the B system. However, given the importance of homozygotes for the tested hypotheses, we also provided the results in A1A1 and B1B1 homozygotes. The association between Taq1 'A' and 'B' polymorphism and [
123 I]IBZM-binding potential was evaluated by ANOVA with Taq1 'A' or 'B' status, diagnosis and age as covariates. Since the association between Taq1 'A' and 'B' polymorphism and substance abuse has been documented in subjects of European origin, but not in subjects of African origin, we also performed an analysis restricted to EA subjects. When relevant, we provided the ANCOVA agecorrected values. All tests were two-tailed, and P = 0.05 was chosen as significance value. Brain imaging data from subsets of this sample have been previously published. 21, 29 
